^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Canhelp-Origin® Assay

Type:
Other Approval
Related tests:
Evidence

News

4ms
Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China. (PubMed, BMC Cancer)
We recommend a CUP diagnostic strategy involving the use of targeted antibody panels as per histological findings that is potentially applicable in clinical practice. The markers TRPS1, INSM1, and P16 expression, as well as HPV and EBER testing are particularly valuable in this aspect. Molecular testing is also predictive of survival rates.
Journal • Retrospective data
|
NKX2-1 (NK2 Homeobox 1) • GATA3 (GATA binding protein 3) • NAPSA (Napsin A Aspartic Peptidase) • PAX8 (Paired box 8) • INSM1 (INSM Transcriptional Repressor 1) • TRPS1 (Transcriptional Repressor GATA Binding 1)
|
Canhelp-Origin® Assay
over1year
Canhelp Genomics secures NMPA approval for pan-cancer Tissue-Origin Assay, analysis software (Genomeweb)
"Chinese molecular diagnostics company Canhelp Genomics has received approval from China's National Medical Products Administration (NMPA) for its Canhelp-Origin pan-cancer test and companion analysis software...A PCR-based tissue-of-origin assay, the Canhelp-Origin Test can measure the gene expression pattern of 90 specific markers of tissue samples and classifies 21 major tumor types that cover more than 95 percent of solid tumors by incidence, the company said."
Non-US regulatory
|
Canhelp-Origin® Assay